Study on Tazemetostat for Treating Malignant Peripheral Nerve Sheath Tumors

Inclusion Criteria

• Have a confirmed diagnosis of malignant peripheral nerve sheath tumor that has returned, not responded to treatment, or spread, and can be measured by scans.
• Be 12 years or older.
• Be in good overall health, with specific performance scores based on age.
• Have recovered from any side effects of previous cancer treatments and meet specific timeframes since last treatment.
• Have not been treated with tazemetostat or similar drugs before.
• Have adequate blood counts and organ function based on lab tests.
• Have no more than one active cancer at the time of joining the study.
• Agree to use effective birth control methods during the study and for a specified time after the last dose of tazemetostat.
• Provide written informed consent to participate in the study.

Exclusion Criteria

• Currently taking other cancer treatments or certain medications that affect how tazemetostat works.
• Have an uncontrolled active infection.
• Have a history of certain blood cancers or other specific medical conditions.
• Have major heart problems or conditions that could increase the risk of complications.
• Are pregnant or breastfeeding.
• Have received a live vaccine within 30 days before starting the study.
• Are unable to take oral medication or have digestive issues that affect medication absorption.
• Are allergic to tazemetostat or its ingredients.